{"id":24349,"date":"2026-02-02T09:00:00","date_gmt":"2026-02-02T07:00:00","guid":{"rendered":"https:\/\/ibsal.es\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/"},"modified":"2026-08-04T12:53:56","modified_gmt":"2026-08-04T10:53:56","slug":"usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer","status":"publish","type":"post","link":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/","title":{"rendered":"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><em>Nature Reviews Gastroenterology &amp; Hepatology<\/em><\/strong><strong> publishes the article, which provides a comprehensive, critical, and up-to-date assessment of the current state of knowledge on cholangiocarcinoma and summarizes the major scientific advances made worldwide in recent years<\/strong><\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\"><strong>A total of 147 international thought leaders from 35 countries participated in updating the Consensus as part of the European COST Precision-BTC Network, coordinated by Professor Roc\u00edo I. R. Mac\u00edas<\/strong><\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">Cholangiocarcinoma is the second most common primary liver cancer worldwide. Although it is still considered a rare cancer, its incidence is increasing globally, partly due to rising risk factors and improvements in diagnostic techniques. Despite the advances made in recent years in understanding the disease and the approval of new treatments that have helped improve patient survival, cholangiocarcinoma remains a highly aggressive tumor with a poor prognosis following diagnosis.  <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"851\" src=\"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig2_HTML-1024x851.png\" alt=\"\" class=\"wp-image-19947\" srcset=\"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig2_HTML-1024x851.png 1024w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig2_HTML-300x249.png 300w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig2_HTML-768x638.png 768w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig2_HTML-1536x1277.png 1536w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig2_HTML-2048x1703.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n<p class=\"wp-block-paragraph\">Global Mortality from Cholangiocarcinoma.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">In this context, the University of Salamanca (USAL) and the Salamanca Institute for Biomedical Research (IBSAL) have played a leading role in developing the most recent version of the \u201cInternational Consensus on Biliary Tract Cancer or Cholangiocarcinoma (CCA),\u201d which comprehensively addresses the basic, molecular, translational, and clinical aspects of this disease. The document was recently published by the prestigious journal <em>*Nature Reviews Gastroenterology &amp; Hepatology<\/em>*. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">The study was led by researchers from IIS Biogipuzkoa and the CIBER for Liver and Digestive Diseases (CIBERehd), in collaboration with the European Network for the Study of Cholangiocarcinoma (ENS-CCA), a multidisciplinary and collaborative network of internationally recognized prestige in the field of biliary tract tumors. The article provides a critical and comprehensive assessment of current knowledge about the disease, integrating the advances made in recent years by numerous research groups and patient associations around the world. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">The new consensus update was developed within the framework of the European COST Precision-BTC Network and involved the participation of professors Roc\u00edo I. R. Mac\u00edas, Jos\u00e9 Juan Garc\u00eda Mar\u00edn, and Elisa Lozano, who coordinated and made significant contributions to the sections on biomarkers and preclinical models.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">It should also be noted that the COST Action Precision-BTC Network is coordinated by Professor Roc\u00edo I. R. Mac\u00edas, a professor in the Department of Physiology and Pharmacology at the University of Salamanca and a member of the HEVEPHARM Research Group (Experimental Hepatology and Drug Delivery). This initiative was launched in 2023 with the goal of advancing the development of precision medicine for patients with bile duct cancer. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\"><strong>Third International Consensus: Key Aspects, Future Research, and Emerging Treatments<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">This article represents the third international consensus in this field, following the editions published in 2016 and 2020, which together have accumulated more than 3,300 citations in the <em>Scopus<\/em> database. The updated document provides an in-depth review of the main basic, translational, and clinical aspects of cholangiocarcinoma, incorporates new perspectives on emerging and promising treatments, and defines strategic development pathways and research priorities for the coming years. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">Among the most relevant recommendations, the consensus highlights the need for an appropriate anatomical, histological, and molecular classification of tumors, which has the potential to significantly impact both current and future treatments as well as the evaluation of patients by multidisciplinary committees.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"785\" src=\"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig1_HTML-1024x785.png\" alt=\"\" class=\"wp-image-19946\" srcset=\"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig1_HTML-1024x785.png 1024w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig1_HTML-300x230.png 300w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig1_HTML-768x588.png 768w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig1_HTML-1536x1177.png 1536w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/41575_2025_1153_Fig1_HTML.png 1951w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n<div style=\"height:0px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">Anatomical subtypes of cholangiocarcinoma and their most common genetic alterations.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">Furthermore, key research priorities include identifying methods for early detection, developing biomarkers that predict treatment response, improving our understanding of the modulation of the tumor microenvironment, and gaining a deeper understanding of the role of local therapies and their combination with systemic treatments.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">The experts\u2019 recommendations were developed through a rigorous consensus-building process known as the Delphi method, in which 147 international thought leaders from 35 countries in Europe, North America, Latin America, Asia, Africa, and Oceania participated, highlighting the document\u2019s global scope and the broad scientific consensus reached.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">Developing this international consensus has posed a significant organizational and scientific challenge, due both to the large number of experts and patient organizations involved and to the diversity of the issues evaluated. Nevertheless, the result is a clear example of international collaboration aimed at clarifying the key elements of the disease and defining future priorities in education, research, and treatment. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\"><strong>COST Precision-BTC Network Action: Precision Medicine for Biliary Tract Cancer<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">COST Actions are interdisciplinary research networks that bring together researchers and innovators to address a specific topic over a four-year period. Open to all fields of science and technology, they bring together researchers from academia, small and medium-sized enterprises, public institutions, and other relevant organizations, providing an inclusive, pan-European environment for the development of scientific collaboration networks. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/BTC-NETWORK-GROUP-1-1024x683.jpg\" alt=\"\" class=\"wp-image-19948\" srcset=\"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/BTC-NETWORK-GROUP-1-1024x683.jpg 1024w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/BTC-NETWORK-GROUP-1-300x200.jpg 300w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/BTC-NETWORK-GROUP-1-768x512.jpg 768w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/BTC-NETWORK-GROUP-1-1536x1024.jpg 1536w, https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/BTC-NETWORK-GROUP-1-2048x1365.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n<p class=\"wp-block-paragraph\">Group photo taken at the most recent conference of the COST Precision-BTC Network.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">The COST Precision-BTC Network Action, coordinated by Professor Roc\u00edo I. R. Mac\u00edas, was launched in 2023 with the goal of promoting precision medicine for patients with biliary cancer. As part of this effort, the initiative has received 600,000 euros in funding from the European Union for its first three years, intended to foster collaboration through mobility programs for young researchers, training schools, webinars, scientific conferences, and a mentoring program (<a href=\"https:\/\/precision-btc.eu\">https:\/\/precision-btc.eu<\/a>). <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">Currently, the network has more than 600 members, and in its first two years of operation, it has facilitated the publication of more than 55 collaborative scientific articles. In addition, it has secured nearly 8 million euros in European funding for joint research projects and has developed highly informative materials for both healthcare professionals and patients, which have been translated into several languages. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\"><strong>International Cholangiocarcinoma Day<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">All of these achievements take on special significance during Cholangiocarcinoma Awareness Month and, in particular, on International Cholangiocarcinoma Day, which will be observed on February 19.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">To mark this occasion, the facade of the University of Salamanca and other iconic buildings in the city will once again be illuminated in green to join the campaign organized by the patient association ATUVIBI (#IluminaEnVerde2026).<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">This symbolic gesture reinforces the University of Salamanca\u2019s commitment to raising social awareness, conducting research, and supporting initiatives that promote a more informed, compassionate, and engaged society, reminding us that every light turned on is a way to show support and affirm that hope is also built through institutions.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\"><strong>Article Information:<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.nature.com\/articles\/s41575-025-01153-w\">Cholangiocarcinoma 2026: Current Status, Unmet Needs, and Priorities<\/a>. Banales JM*, Rodrigues PM*, Aff\u00f2 S, Andersen JB, Aspichueta P, Boulter L, Bridgewater J, Calvisi DF, Cardenas A, Cardinale V, Carpino G, Coulouarn C, Dopazo C, Edeline J, Fabris L, Folseraas T, Forner A, Goeppert B, Heikenwalder M, Kendall TJ, Khan SA, Kl\u00fcmpen HJ, Koerkamp BG, Lamarca A, Lindsey S, Lleo A, Luedde T, Macias RIR, Morement H, Nault JC, Olaizola P, Perugorria MJ, Raggi C, Rimassa L, Saborowski A, Valle JW, Vithayathil M, Vogel A, Braconi C;   <em>International CCA Consensus Consortium. Nat Rev Gastroenterol Hepatol <\/em>  Jan 2026;23(1):65-96. doi: 10.1038\/s41575-025-01153-w <\/p>\n\n<p class=\"wp-block-paragraph\">PMID: 41372578<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p class=\"wp-block-paragraph\">For more information: Roc\u00edo I.R. Mac\u00edas, professor in the Department of Physiology and Pharmacology at USAL. HEVEPHARM Research Group. Experimental Hepatology and Drug Delivery. University of Salamanca\/IBSAL\/CIBEREHD. Email: <a href=\"mailto:rociorm@usal.es\">rociorm@usal.es<\/a> Phone: 923294500, ext. 1912    <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nature Reviews Gastroenterology &amp; Hepatology publishes the article, which provides a comprehensive, critical, and up-to-date assessment of the current state of knowledge on cholangiocarcinoma and summarizes the major scientific advances [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":24350,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[238,239],"tags":[242],"class_list":["post-24349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-news-highlights","tag-cancer-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.12 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d | IBSAL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d\" \/>\n<meta property=\"og:description\" content=\"Nature Reviews Gastroenterology &amp; Hepatology publishes the article, which provides a comprehensive, critical, and up-to-date assessment of the current state of knowledge on cholangiocarcinoma and summarizes the major scientific advances [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"IBSAL\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T07:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-04T10:53:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/HEVEPHARM-scaled-e1770020539988.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1442\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sergi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sergi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/\"},\"author\":{\"name\":\"Sergi\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\"},\"headline\":\"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d\",\"datePublished\":\"2026-02-02T07:00:00+00:00\",\"dateModified\":\"2026-08-04T10:53:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/\"},\"wordCount\":1161,\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/HEVEPHARM-scaled-e1770020539988.jpg\",\"keywords\":[\"Cancer\"],\"articleSection\":[\"News\",\"News highlights\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/\",\"name\":\"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d | IBSAL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/HEVEPHARM-scaled-e1770020539988.jpg\",\"datePublished\":\"2026-02-02T07:00:00+00:00\",\"dateModified\":\"2026-08-04T10:53:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/HEVEPHARM-scaled-e1770020539988.jpg\",\"contentUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/HEVEPHARM-scaled-e1770020539988.jpg\",\"width\":2560,\"height\":1442},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibsal.es\\\/en\\\/institute-of-biomedical-research-of-salamanca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\",\"name\":\"IBSAL\",\"description\":\"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n\",\"alternateName\":\"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibsal.es\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\",\"name\":\"Sergi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"caption\":\"Sergi\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d | IBSAL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/","og_locale":"en_US","og_type":"article","og_title":"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d","og_description":"Nature Reviews Gastroenterology &amp; Hepatology publishes the article, which provides a comprehensive, critical, and up-to-date assessment of the current state of knowledge on cholangiocarcinoma and summarizes the major scientific advances [&hellip;]","og_url":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/","og_site_name":"IBSAL","article_published_time":"2026-02-02T07:00:00+00:00","article_modified_time":"2026-08-04T10:53:56+00:00","og_image":[{"width":2560,"height":1442,"url":"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/HEVEPHARM-scaled-e1770020539988.jpg","type":"image\/jpeg"}],"author":"Sergi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sergi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/#article","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/"},"author":{"name":"Sergi","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97"},"headline":"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d","datePublished":"2026-02-02T07:00:00+00:00","dateModified":"2026-08-04T10:53:56+00:00","mainEntityOfPage":{"@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/"},"wordCount":1161,"image":{"@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/HEVEPHARM-scaled-e1770020539988.jpg","keywords":["Cancer"],"articleSection":["News","News highlights"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/","url":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/","name":"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d | IBSAL","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/#primaryimage"},"image":{"@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/HEVEPHARM-scaled-e1770020539988.jpg","datePublished":"2026-02-02T07:00:00+00:00","dateModified":"2026-08-04T10:53:56+00:00","author":{"@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97"},"breadcrumb":{"@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/#primaryimage","url":"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/HEVEPHARM-scaled-e1770020539988.jpg","contentUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2026\/02\/HEVEPHARM-scaled-e1770020539988.jpg","width":2560,"height":1442},{"@type":"BreadcrumbList","@id":"https:\/\/ibsal.es\/en\/usal-and-ibsal-lead-the-sections-on-biomarkers-and-preclinical-models-in-the-new-international-consensus-on-biliary-tract-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibsal.es\/en\/institute-of-biomedical-research-of-salamanca\/"},{"@type":"ListItem","position":2,"name":"USAL and IBSAL lead the sections on biomarkers and preclinical models in the new \u201cInternational Consensus on Biliary Tract Cancer\u201d"}]},{"@type":"WebSite","@id":"https:\/\/ibsal.es\/en\/#website","url":"https:\/\/ibsal.es\/en\/","name":"IBSAL","description":"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n","alternateName":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibsal.es\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97","name":"Sergi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","caption":"Sergi"}}]}},"_links":{"self":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/24349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/comments?post=24349"}],"version-history":[{"count":1,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/24349\/revisions"}],"predecessor-version":[{"id":24353,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/24349\/revisions\/24353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media\/24350"}],"wp:attachment":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media?parent=24349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/categories?post=24349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/tags?post=24349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}